Advertisement

Topics

Frost & Sullivan Publishes Update Coverage Report on RedHill Biopharma Ltd.: Net revenues for 2017 met expectations at $4M; likely capital raising in mid-2018 when Phase III results for Crohn's disease are announced; Price target raised to NIS 2.59

07:13 EDT 14 Mar 2018 | FinanzNachrichten

Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program TEL AVIV, Israel, March 14, 2018 /PRNewswire/ --TASE analysis project was launched in 2016 in o...

Original Article: Frost & Sullivan Publishes Update Coverage Report on RedHill Biopharma Ltd.: Net revenues for 2017 met expectations at $4M; likely capital raising in mid-2018 when Phase III results for Crohn's disease are announced; Price target raised to NIS 2.59

NEXT ARTICLE

More From BioPortfolio on "Frost & Sullivan Publishes Update Coverage Report on RedHill Biopharma Ltd.: Net revenues for 2017 met expectations at $4M; likely capital raising in mid-2018 when Phase III results for Crohn's disease are announced; Price target raised to NIS 2.59"

Advertisement
Quick Search
Advertisement
Advertisement